Twist Bioscience (TWST) net assets (shareholders' equity)
Twist Bioscience (TWST) had net assets of $888.02M at the end of fiscal 2026 (September 30, 2026). That is 87.8% higher than the $472.96M of fiscal 2025. Figures as of 19 Nov 2026, 11:31 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Net assets, fiscal 2026
- $888.02M
- Change on fiscal 2025
- +87.8%
- Growth, 5 years
- +8.9% a year
- Highest on record
- $888.02Mfiscal 2026
- Lowest on record
- -$201.42Mfiscal 2018
- Fiscal years on record
- 102017–2026
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Twist Bioscience net assets (shareholders' equity), in more detail
Over the five fiscal years to 2026 net assets grew at a compound 8.9% a year. Across the 10 fiscal years on record (2017–2026), the highest was $888.02M in fiscal 2026 and the lowest -$201.42M in fiscal 2018.
Net assets by fiscal year
Twist Bioscience net assets (shareholders' equity), year by year
| Fiscal year | Net assets | Change | Year ended |
|---|---|---|---|
| 2026 | $888.02M | 87.8% up | |
| 2025 | $472.96M | 0.1% up | |
| 2024 | $472.69M | 24.2% down | |
| 2023 | $623.43M | 21.0% down | |
| 2022 | $789.39M | 35.9% up | |
| 2021 | $580.82M | 72.7% up | |
| 2020 | $336.26M | 121.1% up | |
| 2019 | $152.08M | — | |
| 2018 | -$201.42M | — | |
| 2017 | -$133.36M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.
How to read it
Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.
Net assets at health care companies of similar size
| Company | Net assets | Fiscal year |
|---|---|---|
| TG Therapeutics TGTX | $648.02M | 2025 |
| Praxis Precision Medicines PRAX | $878.14M | 2025 |
| Twist Bioscience TWST | $888.02M | 2026 |
| Protagonist Therapeutics PTGX | $614.71M | 2025 |
| Krystal Biotech KRYS | $1.22B | 2025 |
| 10x Genomics TXG | $796.33M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Twist Bioscience, figure by figure
- Twist Bioscience market cap
- Twist Bioscience revenue
- Twist Bioscience earnings
- Twist Bioscience earnings per share (EPS)
- Twist Bioscience P/E ratio
- Twist Bioscience P/S ratio
- Twist Bioscience P/B ratio
- Twist Bioscience free cash flow
- Twist Bioscience operating margin
- Twist Bioscience dividend
- Twist Bioscience shares outstanding
- Twist Bioscience total debt
- Twist Bioscience cash on hand
- Twist Bioscience total assets
- Twist Bioscience total liabilities
- Twist Bioscience return on equity (ROE)
- Twist Bioscience return on invested capital (ROIC)
Twist Bioscience (TWST) overview: price, valuation and scorecardAll health care companies by market value
Twist Bioscience net assets (shareholders' equity): questions and answers
What are Twist Bioscience's net assets?
Twist Bioscience (TWST) had net assets of $888.02M at the end of fiscal 2026 (September 30, 2026). That is 87.8% higher than the $472.96M of fiscal 2025.
What is the growth rate of Twist Bioscience's net assets?
Over the five fiscal years to 2026 net assets grew at a compound 8.9% a year.
What are the highest and lowest net assets figures on record for Twist Bioscience?
Across the 10 fiscal years on record (2017–2026), the highest was $888.02M in fiscal 2026 and the lowest -$201.42M in fiscal 2018.
How is Twist Bioscience's net assets calculated?
Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Twist Bioscience it is on record here for 10 fiscal years, 2017 to 2026.
Fiscal years are named for the calendar year they end in.
Learn: net assets (shareholders' equity)
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Twist Bioscience (TWST) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/TWST/net-assets
Underlying data: the company's filings with the SEC and Yahoo Finance.